An Observational Study of Statin Treatment Induced HDL Changes (SIRIUS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim with this study is to investigate the effect of statin induced changes in HDL-C on all cause mortality and CVD with adjustment for changes in other blood lipids and clinical parameters in Sweden, UK and the Netherlands.
Condition or disease
An observational study of statin treatment induced HDL changes - effect on cardiovascular disease
Time to first occurrence of hospitalization for acute myocardial infarction, unstable angina pectoris or ischemic stroke related to changes in HDL-C [ Time Frame: 1st of January 2004 to 31st December 2010 ]
Secondary Outcome Measures
The effect of statin induced changes in HDL-C (per mmol/L) on a composite endpoint including unstable angina pectoris, myocardial infarction, ischemic stroke and all cause mortality. [ Time Frame: 1st of January 2004 to 31st December 2010 ]
Time to first occurence of hospitalization for acute myocardial infarction, unstable angina pectoris or ischemic stroke and ischemic heart disease mortality related to changes in HDL-C. [ Time Frame: 1st of January 2004 to 31st December 2010 ]
The relationships between acquired HDL levels after statin treatment on the primary endpoint and the effect of HDL increase on the primary endpoint for different levels of baseline HDL [ Time Frame: 1st of January 2004 to 31st December 2010 ]
Potential interactions between baseline HDL and HDL increase and other factors like age, gender, treatment and co-morbidity on the primary endpoint [ Time Frame: 1st of January 2004 to 31st December 2010 ]
The health economic consequences of increasing HDL-C with statin treatment [ Time Frame: 1st of January 2004 to 31st December 2010 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 86 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who received a first prescription of a statin (ATC code C10AA) between 1st of January 2004 and 31st of December 2010. Swedish data will be extracted from medical records and national registers and for UK and the Netherlands from central registers.
Started treatment with statins within the observation period (2004-2010)
The patient must have valid baseline and follow-up measurements for HDL-C and LDL-C.